



PATIENT

Elvis Scholz

SPECIES

Canine

BREED

Shepherd Mix

SEX

Neutered Male

AGE

11 Years

WEIGHT

31.8 kg

INTERPRETED BY

Sara Brethel DVM,
DACVIM (Cardiology)

IMAGING PERFORMED BY

Kelly Reschny

HOSPITAL NAME

Fergus Vet Hospital

REFERRING VET

Dr. Sutton

INVOICE

14413

DATE

03/18/26

PRESENTING CLINICAL SIGNS

- mitral valve disease

Abnormal PE/Chem/CBC/UA Results: patient diary attached.

HOLTER MONITOR RHYTHM ASSESSMENT AND FINDINGS

Assessment

The underlying rhythm is atrial fibrillation with a mean heart rate of 141 beats per minute. There are occasional ventricular ectopic beats, however, the majority of them display a long, short sequence consistent with phase 3 aberrancy and Ashman's phenomenon.

Findings

- Atrial fibrillation with phase 3 aberrancy and a mean heart rate of 141 beats per minute.

RECOMMENDATIONS

The patient has atrial fibrillation and with the mean heart rate being greater than 124 beats per minute, additional antiarrhythmic therapy and control is indicated at this time. It is unclear if the patient requires Sotalol therapy.

Based upon this current Holter monitor, Sotalol is not indicated, especially with the ventricular complexes not being truly ventricular in origin, rather phase 3 aberrancy. However, if the patient has been on Sotalol for over a year, I would be cautious about stopping it. I do think diltiazem should be implemented. Diltiazem at a dose of 0.50 to 1.0 mg/kg every 8 hours for the non-extended release. If using the extended-release formulation, the dose is 2 mg/kg twice a day. If using the extended release, only using the brand Dilacor, this particular brand comes in 240 mg tablets.

There are four internal tablets within the capsule and clients are instructed to open the capsule, inspect the tablets, and then give the amount of tablets required for the dose, bearing in mind that when getting it from pharmacies, you need to specifically say the brand and ensure that the tablets are within the capsule, otherwise a serious overdose can occur.

If considering stopping the Sotalol therapy, I would taper it, i.e. giving one tablet in the morning, half a tablet in the evening for four days, half a tablet twice a day for four days, half a tablet once a day for four days, and then discontinuing it. This medication cannot be stopped abruptly either.

Patients can be on Sotalol and diltiazem at the same time. Can consider rechecking the Holter after starting diltiazem in four to six weeks. If there's optimal control and no significant ventricular ectopics, then I would likely keep the therapies the same at this time. If there's optimal control in four to six weeks, a recheck Holter would be recommended again in six months.

Looking through the medications, Pimobendan is not listed as a therapy. If the patient is not on Pimobendan, they should be started on it, especially with a history of a DCM phenotype and congestive heart failure. A dose of 0.27 to 0.32 mg/kg twice daily is recommended.

